Lymphoma News

Lymphoma News

FDA Panel Votes on Polivy Combo for First-Line Treatment of DLBCL

Publish Date March 14, 2023

An FDA panel voted in favor of approving polatuzumab vedotin in combination with R-CHP for previously untreated DLBCL.

Chest CT Prior to Allo-HSCT Deemed Beneficial for Spotting Abnormalities

Publish Date February 28, 2023

Patients with abnormal chest CTs had worse overall survival, nonrelapse mortality, and pulmonary-related death after allo-HSCT.

Clonal Hematopoiesis More Prevalent in Pediatric Cancer Survivors

Publish Date February 23, 2023

Survivors of pediatric cancer have a higher rate of clonal hematopoiesis than their peers at any age, a study suggests.

Zamtocabtagene Autoleucel Produces High ORR in Relapsed/Refractory DLBCL

Publish Date February 21, 2023

Zamtocabtagene autoleucel produced responses in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 2 trial.

“Severe4” Predicts Outcomes of CAR T-Cell Therapy in Relapsed/Refractory DLBCL

Publish Date February 14, 2023

A prognostic index called “Severe4” can predict outcomes of CAR T-cell therapy in patients with relapsed/refractory DLBCL, a study suggests.

At-Home Medication Errors May Be Common for Children With Leukemia, Lymphoma

Publish Date February 7, 2023

Medication errors may be common in children with leukemia or lymphoma, and these errors can lead to serious harm, a new study suggests.

Treatment May Increase Risk of Colorectal Cancer in Hodgkin Lymphoma Survivors

Publish Date February 6, 2023

Hodgkin lymphoma patients treated with subdiaphragmatic radiation and/or procarbazine have an increased risk of developing colorectal cancer, a study suggests.

Jaypirca Approved for Relapsed/Refractory Mantle Cell Lymphoma

Publish Date January 30, 2023

As a noncovalent inhibitor of BTK, pirtobrutinib is able to reestablish BTK inhibition in patients previously treated with covalent BTK inhibitors.

Epcoritamab Shows Promise in Large B-Cell Lymphoma

Publish Date January 27, 2023

Epcoritamab elicits durable responses in patients with relapsed or refractory large B-cell lymphoma.

Brukinsa Gains Approval for Chronic Lymphocytic Leukemia

Publish Date January 23, 2023

The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.

Posoleucel Deemed Effective Against Viral Infections in Allogeneic HSCT Recipients 

Publish Date January 13, 2023

Posoleucel appears safe and effective for treating refractory viral infections occurring after allogeneic hematopoietic stem cell transplant.

Outcomes Superior With Peripheral Blood vs Bone Marrow Transplants in PTCL

Publish Date January 13, 2023

Researchers observed improvements in overall survival and progression-free survival with peripheral blood vs bone marrow transplants.

AstraZeneca Will Withdraw Lumoxiti From US Market

Publish Date January 12, 2023

Lumoxiti was approved by the FDA in September 2018 for the treatment of adults with relapsed or refractory hairy cell leukemia.

CARMEN Regimen Shows Promise in MYC-Rearranged Aggressive Lymphoma

Publish Date January 6, 2023

The CARMEN regimen appears effective in patients with MYC-rearranged aggressive lymphoma, including those who are HIV-positive.

ASH 2022: MCL Trials Break New Ground, May Change Practice

Publish Date January 5, 2023

Mantle cell lymphoma trials presented at ASH 2022 have broken new ground, shown promising results, and may change practice, according to researchers.

High EFS, High Rate of Thrombosis With Crizotinib Plus Chemo in Pediatric ALCL

Publish Date January 5, 2023

Crizotinib plus chemotherapy appears effective for pediatric patients with newly diagnosed ALCL, but the combination increases the risk of thrombosis.

Delaying HSCT More Than 4 Weeks After COVID-19 Diagnosis May Decrease Risk of Death

Publish Date January 4, 2023

Undergoing HSCT within 4 weeks of SARS-CoV-2 infection is associated with an increased risk of death at 90 days after HSCT, real-world data suggest.

ASH 2022: New Findings in CLL

Publish Date December 28, 2022

Research in patients with CLL showed that zanubrutinib can outperform ibrutinib, a triplet is effective for high-risk CLL, cell death may predict the depth of response, and a CAR T-cell therapy is likely not an option for CLL patients.

Lunsumio Approved for Relapsed or Refractory Follicular Lymphoma

Publish Date December 28, 2022

The FDA has approved Lunsumio (mosunetuzumab-axgb) to treat adults with relapsed/refractory follicular lymphoma after 2 or more lines of systemic therapy.

ASH 2022: Trials Show Promising Results in Follicular Lymphoma

Publish Date December 20, 2022

Results from 4 trials presented at ASH 2022 may help inform the treatment of newly diagnosed and relapsed/refractory follicular lymphoma.